Compass Wealth Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Compass Wealth Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-635	Closed	-$51.5K	–	423
2025 Q1	$51.5K	Buy	635 +200	+46%	+$17.9K	0.01%	243
2024 Q4	$39.2K	Hold	435	–	–	0.01%	266
2024 Q3	$43K	Hold	435	–	–	0.01%	266
2024 Q2	$40.3K	Hold	435	–	–	0.01%	273
2024 Q1	$41.3K	Hold	435	–	–	0.01%	266
2023 Q4	$38.8K	Buy	435 +30	+7%	+$2.23K	0.01%	265
2023 Q3	$29.6K	Hold	405	–	–	0.01%	282
2023 Q2	$33.7K	Hold	405	–	–	0.01%	282
2023 Q1	$30.9K	Hold	405	–	–	0.01%	291
2022 Q4	$33.6K	Buy	+405	New	+$32.8K	0.01%	272

Other funds holding XBI

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return

Compass Wealth Management's XBI Position: Q2 2025 in Review

Compass Wealth Management sold out of State Street SPDR S&P Biotech ETF (XBI) in Q2 2025, closing a stake of 635 shares — an estimated $51.5K sold.

Compass Wealth Management first reported a position in XBI in Q4 2022 and held it in 10 quarters. The position peaked at $51.5K in Q1 2025. 625 funds tracked by Wall St. Rank hold XBI as of Q2 2025.

Compass Wealth Management reported no remaining State Street SPDR S&P Biotech ETF position as of Q2 2025 after selling out during the quarter.
Compass Wealth Management sold 635 State Street SPDR S&P Biotech ETF shares in Q2 2025, an estimated $51.5K.
Compass Wealth Management first reported a position in State Street SPDR S&P Biotech ETF in Q4 2022 and held it in 10 quarters.
Compass Wealth Management's State Street SPDR S&P Biotech ETF position peaked at $51.5K in Q1 2025.
625 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2025.

Based on Compass Wealth Management's 13F filing for Q2 2025, filed 8 Aug 2025.